Bristol-Myers Squibb (BMY) Tops Q4 EPS by 6c; Issues Light FY15 Outlook

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $4.26 billion versus the consensus estimate of $4.02 billion.

Bristol-Myers Squibb sees FY2015 EPS of $1.55-$1.70, versus the consensus of $1.71.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• AB Science reports phase 1 data for AB8939 plus venetoclax in AML
• JPMorgan Upgrades Primoris Services Corporation (PRIM) to Overweight